论文部分内容阅读
目的探讨血清中人类免疫缺陷病毒1型反式激活蛋白(HTATIP2/TIP30)和协同刺激分子B7-H4在原发性肝癌中的临床价值,同时了解其与肝癌生物学特性的关系。方法选取2014年1月至2015年1月60例行肝动脉化疗栓塞术(TACE)的原发性肝癌患者为肝癌组,另选60例健康人为对照组,并进一步将肝癌组TACE治疗4周后按疗效分为疗效好组(n=44)与疗效差组(n=16)。留取各组对象血清标本,酶联免疫吸附法检测HTATIP2/TIP30和B7-H4水平,分析肝癌组与对照组、肝癌组治疗前后两指标水平,及其在不同临床特征、不同预后患者中的差异。结果原发性肝癌患者治疗前血清B7-H4水平高于对照组(P<0.01),血清HTATIP2/TIP30水平低于对照组(P<0.01);治疗后肝癌组血清B7-H4水平较治疗前明显降低,但仍高于对照组(P均<0.01),而HTATIP2/TIP30水平较治疗前明显升高(P<0.01),但仍低于对照组(P<0.01)。回溯分析可见,疗效好组治疗前的血清B7-H4水平已低于疗效差组(P<0.01),治疗后两组均降低(P均<0.01),且疗效好组仍低于疗效差组(P<0.01);疗效好组治疗前的血清HTATIP2/TIP30水平已高于疗效差组(P<0.01),两组治疗后与治疗前相比,无统计学差异(P均>0.05),且疗效好组仍高于疗效差组(P<0.01)。血清HTATIP2/TIP30水平降低和B7-H4水平升高与有门脉癌栓及远处转移有关(P均<0.05);与患者性别、年龄、AFP水平无明显相关性(P均>0.05)。血清B7-H4水平升高、TATIP2/TIP30水平降低均提示患者治疗效果不佳(P均<0.05)。结论血清B7-H4水平增高和HTATIP2/TIP30水平降低或可作为原发性肝癌诊断和患者预后预测的血清标志物。
Objective To investigate the clinical value of serum human immunodeficiency virus type 1 transactivator protein (HTATIP2 / TIP30) and costimulatory molecule B7-H4 in primary hepatocellular carcinoma (HCC), and to investigate its relationship with the biological characteristics of hepatocellular carcinoma. Methods From January 2014 to January 2015, 60 patients with primary liver cancer who underwent transcatheter arterial chemoembolization (TACE) were treated with hepatocellular carcinoma (HCC) and 60 healthy controls were selected as control group. TACE of hepatocellular carcinoma According to the curative effect, the curative effect was divided into good effect group (n = 44) and poor efficacy group (n = 16). The serum samples of each group were collected and the levels of HTATIP2 / TIP30 and B7-H4 were detected by enzyme-linked immunosorbent assay. The levels of two indicators before and after treatment in HCC group and control group and HCC group were analyzed, and their differences in clinical features, prognosis difference. Results The level of serum B7-H4 in patients with primary liver cancer before treatment was significantly higher than that in control group (P <0.01), and the level of serum HTATIP2 / TIP30 was lower than that in control group (P <0.01) (P <0.01), while the level of HTATIP2 / TIP30 was significantly higher than that before treatment (P <0.01), but still lower than that of the control group (P <0.01). The retrospective analysis showed that the pretreatment serum B7-H4 level was lower than the poor efficacy group (P <0.01), and both groups were decreased after treatment (P <0.01), and the effective group was still lower than the poor efficacy group (P <0.01). The level of serum HTATIP2 / TIP30 before treatment in treatment group was significantly higher than that in control group (P <0.01). There was no significant difference between the two groups before treatment (P all> 0.05) And the effective group is still higher than the poor efficacy group (P <0.01). Serum levels of HTATIP2 / TIP30 and elevated B7-H4 were correlated with portal vein tumor thrombus and distant metastasis (all P <0.05), but not with gender, age and AFP level (all P> 0.05). Elevated serum levels of B7-H4 and lower levels of TATIP2 / TIP30 all indicate that the treatment effect is poor (all P <0.05). Conclusion Serum B7-H4 levels increased and HTATIP2 / TIP30 levels decreased or can be used as a primary liver cancer diagnosis and prediction of prognosis of patients with serum markers.